This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moraes, D. L. Articles by Givertz, M. M. Search for Related Content PubMed PubMed Citation Articles by Moraes, D. L. Articles by Givertz, M. M. Related Collections Congestive Pulmonary circulation and disease

(Circulation. 2000;102:1718.)
© 2000 American Heart Association, Inc.

Current Perspective

Secondary Pulmonary Hypertension in Chronic Heart Failure

The Role of the Endothelium in Pathophysiology and Management

Denzil L. Moraes, MB, MRCPI; Wilson S. Colucci, MD; Michael M. Givertz, MD

From the Cardiovascular Section, Boston University Medical Center, Boston, Mass.

Correspondence to Wilson S. Colucci, MD, Cardiovascular Section, Boston University Medical Center, 88 E Newton St, Boston, MA 02118. E-mail wilson.colucci{at}bmc.org

	Abstract

Top Abstract Introduction Pathophysiology of "Reactive"... Clinical Implications of... Therapeutic Approaches to... References

 
Abstract—Pulmonary vascular resistance is frequently elevated in patients with chronic left ventricular failure as a result of dysregulation of vascular smooth muscle tone and structural remodeling. The former is reversible over a period of minutes to days by pharmacological vasodilators, whereas the latter is relatively fixed and may resolve only slowly, over months to years. These abnormalities are due, at least in part, to pulmonary vascular endothelial dysfunction that results in impaired nitric oxide availability and increased endothelin expression. In patients with chronic heart failure, the resulting pulmonary hypertension directly affects right ventricular function and may affect exercise capacity, morbidity, and mortality. New treatment strategies, which include the use of agents that increase nitric oxide availability or oppose the actions of endothelin, may improve the structure and function of the pulmonary vasculature in patients with chronic heart failure.

Key Words: heart failure • hypertension, pulmonary • nitric oxide • endothelin

	Introduction

Top Abstract Introduction Pathophysiology of "Reactive"... Clinical Implications of... Therapeutic Approaches to... References

 
The pulmonary circulation is a low-pressure, high-capacity system. At sea level, the normal pulmonary artery systolic pressure is 25 mm Hg, and the pulmonary vascular resistance (PVR) averages 67±30 dynes · s · cm^-5, less than one tenth that of the systemic circulation.¹ The pulmonary vasculature can accommodate large increases in blood flow, as during exercise² or sudden occlusion of a pulmonary artery,³ with little or no increase in pressure.

The pulmonary circulation is a major determinant of right ventricular (RV) afterload and thus determines RV output. Although the thin-walled, distensible RV can accommodate large increases in systemic venous return without a rise in pulmonary artery pressures, even modest increases in pulmonary vascular tone, if acute, can result in RV failure. The pulmonary circulation also regulates venous return to the left ventricle (LV) and thus protects the LV against excess preload. In pulmonary hypertension associated with chronic heart failure, RV afterload and LV preload are increased, leading to further myocardial dysfunction.

	Pathophysiology of "Reactive" Pulmonary Hypertension in Heart Failure

Top Abstract Introduction Pathophysiology of "Reactive"... Clinical Implications of... Therapeutic Approaches to... References

 
Pulmonary hypertension is present when the pulmonary artery systolic pressure exceeds 30 mm Hg or the mean pulmonary artery pressure is 19 mm Hg. In patients with chronic LV dysfunction, an elevation in LV filling pressure results in a "passive" increase in pulmonary venous pressure. Pulmonary venous congestion is frequently associated with a "reactive" increase in PVR, which results in an increased transpulmonary pressure gradient that is superimposed on the pulmonary venous pressure. The pulmonary artery pressure further depends on the performance of the RV. Although the normal RV can generate peak systolic pressures of only 45 to 50 mm Hg, much higher pressures may be achieved if pulmonary hypertension develops slowly so that there is RV hypertrophy. Conversely, if there is RV failure, the pulmonary artery pressure may be relatively low despite marked elevation of the PVR.

Secondary pulmonary hypertension may reflect "remodeling" of the arterial wall with abnormalities of elastic fibers, intimal fibrosis, and medial hypertrophy that result in vascular stiffness and reduced vasodilator responsiveness. Although possibly reversible over time (ie, months), the pulmonary hypertension attributable to structural remodeling is generally referred to as "fixed" because it is not rapidly responsive (ie, minutes to days) to reversal with pharmacological maneuvers.

In most patients with chronic heart failure, the major component of pulmonary hypertension is readily reversed by vasodilators. In the pulmonary vasculature, as in the systemic circulation, the endothelium plays a central role in the local control of tone through the regulated release of nitric oxide (NO) and endothelin (ET). There is growing evidence that the dysregulation of pulmonary vascular tone in disease states, including chronic heart failure, involves alterations in these important counterbalancing systems (Figure 1).

View larger version (25K): [in this window] [in a new window]   Figure 1. Proposed relationship between LV dysfunction and secondary events that may contribute to development of pulmonary hypertension. Increase in pulmonary ET and/or reduction in endothelium-derived NO may cause pathophysiological changes in vessel structure and function, which adversely affect long-term morbidity and mortality. EDP indicates end-diastolic pressure; EC, endothelial cell.

NO-Dependent Pulmonary Vasodilation
Pulmonary vascular endothelial cells elaborate NO, which relaxes vascular smooth muscle cells. Under basal conditions, NO is synthesized by the "constitutive" isoform of NO synthase (NOS), also referred to as NOS3, one of a family of enzymes that catalyze the conversion of L-arginine to L-citrulline. In addition, several substances or physical stimuli act on NOS3 to increase the synthesis and release of NO.⁴ NO diffuses from the endothelial cell into adjacent smooth muscle cells, where it activates soluble guanylyl cyclase, thereby increasing the intracellular concentration of cGMP, which in turn causes smooth muscle cell relaxation by inhibiting calcium release from the sarcoplasmic reticulum. Endothelial cell–derived NO also inhibits smooth muscle cell proliferation and hypertrophy and, acting in concert with prostacyclin, inhibits platelet aggregation and adhesion.⁵

The systemic infusion of N^G-monomethyl-L-arginine (L-NMMA), an analog of L-arginine that inhibits NOS, causes pulmonary hypertension⁶ and accentuates hypoxia-induced pulmonary vasoconstriction in healthy humans.⁷ To avoid potentially confounding systemic effects, investigators have infused NOS inhibitors directly into the pulmonary artery. Celermajer et al⁸ found that intrapulmonary infusion of L-NMMA in children with congenital heart disease and normal pulmonary artery pressures caused a dose-dependent fall in pulmonary blood flow velocity as measured with a Doppler-tipped wire. Because L-NMMA was infused into a subsegmental pulmonary artery, there was no change in pulmonary artery pressure; hence, the decrease in flow reflected an increase in local vascular resistance. Using a similar method in normal adults, Cooper et al⁹ found that L-NMMA caused dose-dependent vasoconstriction, whereas acetylcholine caused dose-dependent vasodilation. Coadministration of L-NMMA and acetylcholine attenuated the dilator effect of acetylcholine. These studies suggest that endothelium-derived NO plays an important role in determining both basal pulmonary vascular tone and dilation to endothelium-dependent stimuli.

Impaired NO-Dependent Pulmonary Vasodilation in Heart Failure
Studies in both experimental models and patients suggest that NO-dependent pulmonary vasodilation is impaired in heart failure. In vitro in pulmonary artery segments from rats with chronic LV failure following myocardial infarction, Ontkean et al¹⁰ found that the vasodilator response to acetylcholine was impaired, whereas that for nitroglycerin was normal, suggesting impaired endothelium-dependent relaxation.

In humans, Porter et al¹¹ used intravascular ultrasound to assess pulmonary artery diameter. They found that intrapulmonary infusion of acetylcholine caused constriction, which was accentuated by inhibition of guanylate cyclase in patients with heart failure and normal pulmonary artery pressures but failed to cause dilation in patients with heart failure and pulmonary hypertension. The endothelium-independent vasodilator nitroglycerin caused pulmonary vasodilation in both groups. Cooper et al¹² extended these observations by measuring pulmonary blood flow velocity during intrapulmonary infusion of L-NMMA. In normal control subjects or patients with heart failure and a normal PVR, L-NMMA caused vasoconstriction, whereas in patients with heart failure and pulmonary hypertension, the vasoconstrictor response to L-NMMA was attenuated. The vasoconstrictor responses to phenylephrine were similar in the 3 groups. Taken together, these clinical studies suggest that basal pulmonary artery NO production is relatively deficient in patients with heart failure and secondary pulmonary hypertension and that the loss of NO-dependent vasodilation may contribute to the development of pulmonary hypertension.

Role of ET in the Regulation of Pulmonary Vascular Tone
ET is a 21-residue vasoactive peptide first isolated in 1988 from endothelial cells by Yanagisawa and colleagues.¹³ Besides being a potent arterial and venous vasoconstrictor, ET exerts long-term effects on cellular phenotype. There are 2 subtypes of receptors for ET, ET_A and ET_B. In the vasculature, ET_A receptors are located on vascular smooth muscle cells where they mediate both vasoconstriction and growth (Figure 2).¹⁴ In contrast, ET_B receptors, found primarily on vascular endothelial cells, mediate vasodilation via the release of NO and prostacyclin. Some ET_B receptors, which may differ pharmacologically from those on endothelial cells, appear to be located on vascular smooth muscle cells where they directly mediate contraction. ET_B receptors also play an important role in ET-1 clearance.¹⁵ The ratio of ET_A to ET_B receptors on human resistance and conduit pulmonary arteries is approximately 9:1,¹⁴ and the net effect of ET-1 in pulmonary arteries is constriction.

View larger version (27K): [in this window] [in a new window]   Figure 2. Physiological interaction between pulmonary endothelial and vascular smooth muscle cells involves a balance between ET-1 and NO production. In chronic LV failure, a relative increase in ET-1 and/or decrease in NO may cause vasoconstriction and smooth muscle cell proliferation. Ach indicates acetylcholine; prepro-ET, preproendothelin; pro-ET, proendothelin; arg, arginine; and SMC, smooth muscle cell.

The availability of several nonpeptide ET receptor antagonists¹⁶ that may be selective or nonselective has helped to clarify the roles of the ET receptor subtypes (the Table). In dogs, vasoconstriction stimulated by ET-1 is attenuated by infusion of an ET_A-selective antagonist.¹⁷ However, an ET_B-selective antagonist may either potentiate or antagonize the vasoconstrictor effect of ET-1.^{17 18} In one study in normal humans, infusion of the ET_A-selective antagonist BQ-123 into the brachial artery caused dose-dependent vasodilation, and infusion of the ET_B-selective agonist sarafotoxin S6c caused vasoconstriction.¹⁹ However, in another study in healthy humans, brachial artery infusion of an ET_B-selective antagonist caused mild vasoconstriction.²⁰ These studies suggest that in the human forearm ET_A receptors uniformly mediate vasoconstriction, whereas ET_B receptors may mediate either dilation or constriction.

View this table: [in this window] [in a new window]   Table 1. Subtype Selectivity of Endothelin Receptor Agonists and Antagonists

The relative roles of ET receptor subtypes in regulating pulmonary vascular tone in vivo in humans has not been directly studied with intrapulmonary infusion techniques. However, in vitro in human endothelium-denuded pulmonary arteries, ET-1 stimulates contraction, which is inhibited by the ET_A-selective antagonist BQ-123, whereas the ET_B-selective agonist sarafotoxin S6c does not cause contraction.²¹ Likewise, other studies that have used human pulmonary resistance arteries and endothelium-denuded intralobar pulmonary arteries have confirmed that ET-1 causes pulmonary artery vasoconstriction predominantly via ET_A receptors, although there is some evidence that ET_B receptors may contribute at low ET-1 concentrations.¹⁸ ET-1–stimulated proliferation of human pulmonary artery smooth muscle cells is mediated by ET_A receptors.²²

ET and Reactive Pulmonary Hypertension in Heart Failure
Plasma ET-1 levels are elevated in children with pulmonary hypertension secondary to congenital heart disease and adults with primary or secondary pulmonary hypertension.²³ Cody et al²⁴ found that patients with severe heart failure had significantly elevated plasma ET-1 levels that correlated best with pulmonary artery pressures and PVR (Figure 3) but not with several other measures of systemic hemodynamics, including cardiac index, pulmonary capillary wedge pressure, and systemic vascular resistance (SVR). These data suggested that ET-1 may be a mediator of, or a marker for, reactive pulmonary hypertension in patients with LV failure.

View larger version (17K): [in this window] [in a new window]   Figure 3. Relationship between mean pulmonary artery pressure (PA) and plasma ET-1 levels in patients with symptomatic chronic heart failure. Reproduced with permission from Reference 24 .

Elevated ET-1 levels in heart failure may be due to increased local production and/or decreased pulmonary clearance. Dupuis et al²⁵ demonstrated that ET-1 is both produced and cleared by the lungs and that ET-1 spillover in the lungs correlates with PVR in patients with heart failure.²⁶ There is increased preproendothelin-1 mRNA and ET-1 staining in pulmonary vascular endothelial cells from rats with chronic heart failure and pulmonary hypertension.²⁷ Likewise, ET-1 immunoreactivity is abundant in pulmonary vascular endothelial cells from patients with primary and secondary pulmonary hypertension.²⁸ In vivo and in vitro data suggest that ET_B receptors mediate ET-1 clearance. Zolk et al²⁹ have recently shown that ET_B receptors are downregulated in failing human myocardium, which may explain, in part, elevation of circulating and tissue ET-1 levels in heart failure. Conversely, cytokines such as tumor necrosis factor- that are upregulated in heart failure can stimulate ET-1 production.³⁰

ET-1 causes concentration-dependent contraction of pulmonary arteries and veins in vitro³¹ and increases in PVR in vivo,³² effects that are mediated predominantly by ET_A receptors.²¹ Vasoconstriction to ET-1 may be enhanced in heart failure because of upregulation of ET_A receptors.³³ ET-1 may also contribute to pathological pulmonary vascular remodeling by causing proliferation and hypertrophy of vascular smooth muscle cells and increased collagen synthesis.³⁴ ET-1–induced proliferation of pulmonary artery smooth muscle cells appears to be mediated primarily by the ET_A receptor.²²

In addition, ET-1 may be involved in mediating angiotensin-stimulated vascular hypertrophy³⁵ and may act in an autocrine or paracrine manner to increase local concentrations of norepinephrine or other pulmonary vasoconstrictors or to inhibit the expression of NOS.³⁶ Conversely, NO produced by pulmonary vascular endothelium may inhibit the expression or activity of ET-1.³¹

	Clinical Implications of Secondary Pulmonary Hypertension in Heart Failure

Top Abstract Introduction Pathophysiology of "Reactive"... Clinical Implications of... Therapeutic Approaches to... References

 
Exercise Capacity
Measures of resting LV function correlate poorly with exercise capacity in patients with chronic heart failure, and there is evidence that the pulmonary vasculature may play a more important role in determining exercise capacity through its effects on RV function. In patients with heart failure, there is an inverse relationship between peak oxygen consumption (O₂) and resting pulmonary arterial pressure or PVR.^{37 38} In addition, although exercise results in a fall in SVR, total pulmonary resistance and PVR remain elevated. These observations led to the suggestion that pulmonary hypertension reduced exercise capacity in patients with LV failure by increasing RV afterload. This thesis is supported by a positive correlation between RV ejection fraction (RVEF) at rest and peak O₂ in patients with LV failure³⁹ and between exercise RVEF and peak O₂ in patients referred for cardiac transplant evaluation.⁴⁰

Of note, recent studies have demonstrated that elevated levels of ET-1 (but not of norepinephrine or vasopressin) measured during exercise correlate inversely with peak exercise capacity in patients with heart failure⁴¹ and that inhaled NO may increase exercise capacity in selected patients with secondary pulmonary hypertension.⁴² Thus, increased ET-1, decreased NO, or both may contribute to exercise intolerance in heart failure by attenuating pulmonary and/or peripheral vasodilation.

Morbidity and Mortality
The extent of secondary pulmonary hypertension may be a determinant of morbidity and mortality in patients with chronic heart failure. In patients with chronic heart failure, pulmonary artery systolic pressure was an independent predictor of the need for cardiac transplant.⁴³ Likewise, death and hospitalization for heart failure were increased in patients with echocardiographic evidence of pulmonary hypertension.⁴⁴ Presumably, a major impact of pulmonary hypertension is on RV function, which is a strong predictor of overall and event-free survival in chronic heart failure.⁴⁰ Plasma ET-1 levels predict mortality in chronic heart failure.⁴⁵

	Therapeutic Approaches to Secondary Pulmonary Hypertension

Top Abstract Introduction Pathophysiology of "Reactive"... Clinical Implications of... Therapeutic Approaches to... References

 
Effects of Standard Therapy
Conventional therapies for heart failure, including ACE inhibitors, ß-blockers, digoxin, and most vasodilators, reduce PVR. The long-term administration of prostacyclin via a continuous infusion, although useful in patients with primary pulmonary hypertension, was associated with excess mortality in patients with severe heart failure.⁴⁶ After successful cardiac transplantation, there is rapid resolution of elevated pulmonary arterial pressures.⁴⁷

Nitric Oxide
Based on the pathophysiology of pulmonary hypertension, strategies to increase NO in the pulmonary vasculature have been developed. We⁴⁸ and others⁴⁹ found that short-term inhalation of NO lowers PVR in patients with moderate to severe heart failure caused by LV dysfunction. The baseline PVR strongly predicted the magnitude of the PVR response to inhaled NO (Figure 4). Surprisingly, inhaled NO did not lower pulmonary artery pressure. Rather, the decreases in transpulmonary gradient and PVR were associated with an increase in pulmonary capillary wedge pressure. LV filling pressure does not increase with inhaled NO in patients with primary pulmonary hypertension who have normal LV function.⁵⁰ The increase in LV filling pressure appears to reflect the effect of increased pulmonary venous return to a poorly compliant LV.⁵¹ The experience with inhaled NO highlights the important interaction between PVR and LV filling in heart failure. Presumably, LV filling pressure does not increase with pulmonary vasodilators such as nitroprusside because they cause a concomitant decrease in LV afterload.

View larger version (16K): [in this window] [in a new window]   Figure 4. Relationship between baseline PVR and percent change in PVR with inhaled NO in patients with symptomatic LV dysfunction.48 Increased response in patients with higher baseline PVR suggests that there may be relative NO deficiency, whereas lack of response in patients with low or normal baseline PVR suggests that NO activity may be adequate to compensate for vasoconstrictor activity.

Because inhaled NO is associated with an increase in LV filling pressure in patients with heart failure and has even been associated with acute pulmonary edema,⁵² it has little or no role in primary therapy. However, inhaled NO may be used as a test for pulmonary vasoreactivity before cardiac transplantation,⁴⁹ as perioperative support in high-risk patients undergoing CABG or valve replacement,⁵³ or to prevent or treat RV failure after cardiac transplantation or implantation of an LV assist device.⁵¹

ET Receptor Antagonists
The development of ET receptor antagonists has provided an important tool to define the role of ET-1 in the pathophysiology of heart failure. Both ET_A-selective and nonselective antagonists improve hemodynamics, ameliorate LV remodeling, and improve survival in animal models of heart failure.⁵⁴ To date, there is relatively little information about the effects of ET-1 antagonists on pulmonary hemodynamics in heart failure. However, in dogs with pacing-induced heart failure and secondary pulmonary hypertension, an ET_A-selective antagonist decreased PVR, whereas an ET_B-selective antagonist had the opposite effect.¹⁷ The implication from this finding is that in heart failure pulmonary ET_A receptors exert a vasoconstrictor effect, whereas ET_B receptors mediate vasodilation. ET_A-selective antagonists also decrease pulmonary hypertension, pulmonary vascular remodeling, and RV hypertrophy in animals with monocrotaline- or hypoxia-induced pulmonary hypertension.⁵⁵

ET Antagonists in Patients With Heart Failure
Bolus administration of the nonselective ET antagonist bosentan to patients with moderate heart failure decreased arterial, right atrial, pulmonary artery, and pulmonary capillary wedge pressures; decreased SVR and PVR by 17% and 33%, respectively; and increased cardiac index.⁵⁶ Two weeks of oral bosentan caused further reductions in SVR and PVR.⁵⁷

In a small, uncontrolled study, a 1-hour infusion of the ET_A-selective antagonist BQ-123 caused modest decreases in SVR and PVR and a small increase in cardiac index.⁵⁸ An intravenous bolus of sitaxsentan,⁵⁹ an ET_A-selective antagonist, in patients with chronic stable heart failure decreased pulmonary artery systolic pressure and PVR but had no effect on SVR, pulmonary capillary wedge pressure, cardiac index, or heart rate (Figure 5).

View larger version (14K): [in this window] [in a new window]   Figure 5. Percent change from baseline at 2 hours in pulmonary artery mean pressure (PAM) and PVR in response to placebo (open bars), Sitaxsentan 1.5 mg/kg (shaded bars), or sitaxsentan 3.0 mg/kg (solid bars) in 24 patients with NYHA functional class III-IV heart failure (*P<0.05 vs placebo).

Given the circumstantial evidence that implicates ET-1 in the pathophysiology of reactive pulmonary hypertension in heart failure, ET antagonists may be particularly effective for the amelioration of pulmonary hypertension and the reversal of RV and pulmonary vascular remodeling. Limited existing data suggest that ET_A selectivity may be desirable with regard to pulmonary vasodilation in heart failure. However, much remains to be learned about both the pharmacology of ET blockade in heart failure and the clinical consequences of this potential new form of therapy.

	Acknowledgments

 
This work was supported by NIH grant HL-52320 (Dr Colucci) and a grant-in-aid (Dr Givertz) and fellowship award (Dr Moraes) from the American Heart Association, Massachusetts Affiliate.

	References

Top Abstract Introduction Pathophysiology of "Reactive"... Clinical Implications of... Therapeutic Approaches to... References

 

1. Grossman W. Clinical measurement of vascular resistance and assessment of vasodilator drugs. In: Grossman W, Baim DS, eds. Cardiac Catheterization, Angiography, and Intervention. Philadelphia, Pa: Lea & Febiger; 1991:143–151.
   
2. Harris P, Segel N, Bishop J. The relationship between pressure and flow in the pulmonary circulation in normal subjects and in patients with chronic bronchitis and mitral stenosis. Cardiovasc Res. 1968;1:73–82.
   
3. Charms BL, Brofman BL, Elder JC, et al. Unilateral pulmonary artery occlusion in man: studies in patients with chronic pulmonary disease. J Thorac Surg. 1958;35:316–331.
   
4. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109–142.[Medline] [Order article via Infotrieve]
   
5. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193–5197.[Abstract/Free Full Text]
   
6. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994;89:2035–2040.[Abstract/Free Full Text]
   
7. Blitzer ML, Loh E, Roddy MA, et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol. 1996;28:591–596.[Abstract]
   
8. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 1993;87:440–446.[Abstract/Free Full Text]
   
9. Cooper CJ, Landzberg MJ, Anderson TJ, et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation. 1996;93:266–271.[Abstract/Free Full Text]
   
10. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res. 1991;69:1088–1096.[Abstract/Free Full Text]
    
11. Porter TR, Taylor DO, Cycan A, et al. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol. 1993;22:1418–1424.[Abstract]
    
12. Cooper CJ, Jevnikar FW, Walsh T, et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol. 1998;82:609–614.[Medline] [Order article via Infotrieve]
    
13. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.[Medline] [Order article via Infotrieve]
    
14. Fukuroda T, Kobayashi M, Ozaki S, et al. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol. 1994;76:1976–1982.[Abstract/Free Full Text]
    
15. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ET_B receptors. J Appl Physiol. 1996;81:1510–1515.[Abstract/Free Full Text]
    
16. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133–138.[Medline] [Order article via Infotrieve]
    
17. Wada A, Tsutamoto T, Fukai D, et al. Comparison of the effects of selective endothelin ET_A and ET_B receptor antagonists in congestive heart failure. J Am Coll Cardiol. 1997;30:1385–1392.[Abstract]
    
18. McCulloch KM, Docherty CC, Morecroft I, et al. Endothelin-B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol. 1996;119:1125–1130.[Medline] [Order article via Infotrieve]
    
19. Love MP, Haynes WG, Gray GA, et al. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996;94:2131–2137.[Abstract/Free Full Text]
    
20. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998;97:752–756.[Abstract/Free Full Text]
    
21. Buchan KW, Magnusson H, Rabe KF, et al. Characterisation of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46–2005. Eur J Pharmacol. 1994;260:221–226.[Medline] [Order article via Infotrieve]
    
22. Zamora MA, Dempsey EC, Walchak SJ, et al. BQ-123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 1993;9:429–433.
    
23. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464–469.
    
24. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504–509.[Abstract/Free Full Text]
    
25. Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996;94:1578–1584.[Abstract/Free Full Text]
    
26. Tsutamoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427–1433.[Abstract]
    
27. Sakai S, Miyauchi T, Sakurai T, et al. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist: increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol. 1996;28:1580–1588.[Abstract]
    
28. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732–1739.[Abstract/Free Full Text]
    
29. Zolk O, Quattek J, Sitzler G, et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 1999;99:2118–2123.[Abstract/Free Full Text]
    
30. Klemm P, Warner TD, Hohlfeld T, et al. Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. Proc Natl Acad Sci U S A. 1995;92:2691–2695.[Abstract/Free Full Text]
    
31. Zellers TM, McCormick J, Wu Y. Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins. Am J Physiol. 1994;267:H139–H147.[Abstract/Free Full Text]
    
32. Lippton HL, Hauth TA, Summer WR, et al. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. J Appl Physiol. 1989;66:1008–1012.[Abstract/Free Full Text]
    
33. Picard P, Smith PJ, Monge JC, et al. Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure. J Cardiovasc Pharmacol. 1998;31:S294–S297.
    
34. Guarda E, Katwa LC, Myers FR, et al. Effect of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130–2134.[Abstract/Free Full Text]
    
35. Moreau P, d’Uscio LV, Shaw S, et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96:1593–1597.[Abstract/Free Full Text]
    
36. Markewitz BA, Michael JR, Kohan DE. Endothelin-1 inhibits the expression of inducible nitric oxide synthase. Am J Physiol. 1997;272:L1078–L1083.[Abstract/Free Full Text]
    
37. Franciosa JA, Baker BJ, Seth L. Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J. 1985;110:807–813.[Medline] [Order article via Infotrieve]
    
38. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34:1802–1806.[Abstract/Free Full Text]
    
39. Baker BJ, Wilen MM, Boyd CM, et al. Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol. 1984;54:596–599.[Medline] [Order article via Infotrieve]
    
40. Di Salvo TG, Mathier M, Semigran MJ, et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143–1153.[Abstract]
    
41. Krum H, Goldsmith R, Wilshire-Clement M, et al. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol. 1995;75:1282–1283.[Medline] [Order article via Infotrieve]
    
42. Koelling TM, Kirmse M, Di Salvo TG, et al. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol. 1998;81:1494–1497.[Medline] [Order article via Infotrieve]
    
43. Rickenbacher PR, Trindade PT, Haywood GA, et al. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. J Am Coll Cardiol. 1996;27:1192–1197.[Abstract]
    
44. Abramson SV, Burke JF, Kelly JJ Jr, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116:888–895.
    
45. Hulsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol. 1998;32:1695–1700.[Abstract/Free Full Text]
    
46. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44–54.[Medline] [Order article via Infotrieve]
    
47. Bhatia SJ, Kirshenbaum JM, Shemin RJ, et al. Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Circulation. 1987;76:819–826.[Abstract/Free Full Text]
    
48. Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation. 1994;90:2780–2785.[Abstract/Free Full Text]
    
49. Kieler-Jensen N, Ricksten SE, Stenqvist O, et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant. 1994;13:366–375.[Medline] [Order article via Infotrieve]
    
50. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173–1174.[Medline] [Order article via Infotrieve]
    
51. Hare JM, Shernan SK, Body SC, et al. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation. 1997;95:2250–2253.[Abstract/Free Full Text]
    
52. Bocchi EA, Bacal F, Auler JO Jr, et al. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol. 1994;74:70–72.[Medline] [Order article via Infotrieve]
    
53. Rich GF, Murphy GD Jr, Roos CM, et al. Inhaled nitric oxide: selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology. 1993;78:1028–1035.[Medline] [Order article via Infotrieve]
    
54. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long- term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976–1982.[Abstract/Free Full Text]
    
55. Oparil S, Chen SJ, Meng QC, et al. Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. Am J Physiol. 1995;268:L95–L100.[Abstract/Free Full Text]
    
56. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732–736.[Medline] [Order article via Infotrieve]
    
57. Sutsch G, Kiowski W, Yan X-W, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262–2268.[Abstract/Free Full Text]
    
58. Cowburn PJ, Cleland JG, McArthur JD, et al. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet. 1998;352:201–202.[Medline] [Order article via Infotrieve]
    
59. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute ET_A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation.2000;101:2922–2927.
    

This article has been cited by other articles:

				E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF]

				L. Ray, M. Mathieu, P. Jespers, I. Hadad, M. Mahmoudabady, A. Pensis, S. Motte, I. R. Peters, R. Naeije, and K. McEntee Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure Exp Physiol, March 1, 2008; 93(3): 434 - 442. [Abstract] [Full Text] [PDF]

				M. Guazzi, M. Samaja, R. Arena, M. Vicenzi, and M. D. Guazzi Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2136 - 2144. [Abstract] [Full Text] [PDF]

				S. M. Kaestle, C. A. Reich, N. Yin, H. Habazettl, J. Weimann, and W. M. Kuebler Nitric oxide-dependent inhibition of alveolar fluid clearance in hydrostatic lung edema Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L859 - L869. [Abstract] [Full Text] [PDF]

				A. A. Olkowski Pathophysiology of Heart Failure in Broiler Chickens: Structural, Biochemical, and Molecular Characteristics Poult. Sci., May 1, 2007; 86(5): 999 - 1005. [Abstract] [Full Text] [PDF]

				D. Merkus, B. Houweling, V. J. de Beer, Z. Everon, and D. J. Duncker Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction J. Physiol., May 1, 2007; 580(3): 907 - 923. [Abstract] [Full Text] [PDF]

				S. Dellegrottaglie, J. Sanz, M. Poon, J. F. Viles-Gonzalez, R. Sulica, M. Goyenechea, F. Macaluso, V. Fuster, and S. Rajagopalan Pulmonary Hypertension: Accuracy of Detection with Left Ventricular Septal-to-Free Wall Curvature Ratio Measured at Cardiac MR Radiology, April 1, 2007; 243(1): 63 - 69. [Abstract] [Full Text] [PDF]

				G. D. Lewis, J. Lachmann, J. Camuso, J. J. Lepore, J. Shin, M. E. Martinovic, D. M. Systrom, K. D. Bloch, and M. J. Semigran Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure Circulation, January 2, 2007; 115(1): 59 - 66. [Abstract] [Full Text] [PDF]

				B. Houweling, D. Merkus, O. Sorop, F. Boomsma, and D. J. Duncker Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction J. Physiol., July 15, 2006; 574(2): 615 - 626. [Abstract] [Full Text] [PDF]

				F. D. Wagner, S. Buz, H. Zais, J. P. Stasch, R. Hetzer, and B. Hocher Humoral and hemodynamic responses after left ventricular assist device implantation and heart transplantation. Experimental Biology and Medicine, June 1, 2006; 231(6): 861 - 864. [Abstract] [Full Text] [PDF]

				M.-S. Tan, C.-Y. Chai, J.-R. Wu, J.-L. Yeh, I.-J. Chen, A.-L. Kwan, A. Y. Jeng, H.-Y. Yang, M.-H. Lee, and Z.-K. Dai Differential Change in Expression of Pulmonary ET-1 and eNOS in Rats After Chronic Left Ventricular Pressure Overload. Experimental Biology and Medicine, June 1, 2006; 231(6): 948 - 953. [Abstract] [Full Text] [PDF]

				S.-H. Chou, C.-Y. Chai, J.-R. Wu, M.-S. Tan, C.-C. Chiu, I.-J. Chen, A. Y. Jeng, C.-I Chang, A.-L. Kwan, and Z.-K. Dai The Effects of Debanding on the Lung Expression of ET-1, eNOS, and cGMP in Rats with Left Ventricular Pressure Overload. Experimental Biology and Medicine, June 1, 2006; 231(6): 954 - 959. [Abstract] [Full Text] [PDF]

				M. A. Arias, F. Garcia-Rio, A. Alonso-Fernandez, I. Martinez, and J. Villamor Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: A randomized, controlled cross-over study Eur. Heart J., May 1, 2006; 27(9): 1106 - 1113. [Abstract] [Full Text] [PDF]

				G. B. Bleeker, M. J. Schalij, P. Nihoyannopoulos, P. Steendijk, S. G. Molhoek, L. van Erven, M. Bootsma, E. R. Holman, E. E. van der Wall, and J. J. Bax Left Ventricular Dyssynchrony Predicts Right Ventricular Remodeling After Cardiac Resynchronization Therapy J. Am. Coll. Cardiol., December 20, 2005; 46(12): 2264 - 2269. [Abstract] [Full Text] [PDF]

				J. J. Lepore, A. Maroo, L. M. Bigatello, G. W. Dec, W. M. Zapol, K. D. Bloch, and M. J. Semigran Hemodynamic Effects of Sildenafil in Patients With Congestive Heart Failure and Pulmonary Hypertension: Combined Administration With Inhaled Nitric Oxide Chest, May 1, 2005; 127(5): 1647 - 1653. [Abstract] [Full Text] [PDF]

				M. Guazzi, G. Tumminello, F. Di Marco, C. Fiorentini, and M. D. Guazzi The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2339 - 2348. [Abstract] [Full Text] [PDF]

				R. Jhaveri, S. Kim, A. R. White, S. Burke, D. E. Berkowitz, and D. Nyhan Enhanced Vasodilatory Responses to Milrinone in Catecholamine-Precontracted Small Pulmonary Arteries Anesth. Analg., June 1, 2004; 98(6): 1618 - 1622. [Abstract] [Full Text] [PDF]

				B. K. Gehlbach and E. Geppert The Pulmonary Manifestations of Left Heart Failure Chest, February 1, 2004; 125(2): 669 - 682. [Abstract] [Full Text] [PDF]

				F. D. Wagner, S. Buz, C. Knosalla, R. Hetzer, and B. Hocher Modulation of Circulating Endothelin-1 and Big Endothelin by Nitric Oxide Inhalation Following Left Ventricular Assist Device Implantation Circulation, September 9, 2003; 108(90101): II-278 - 284. [Abstract] [Full Text] [PDF]